期刊文献+

Oncogenic potential of IDH1R132C mutant incholangiocarcinoma development in mice 被引量:1

Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice
下载PDF
导出
摘要 AIM: To investigate whether IDH1R132 C mutant in combination with loss of p53 and activated Notch signaling promotes intrahepatic cholangiocarcinoma(ICC) development.METHODS: We applied hydrodynamic injection and sleeping beauty mediated somatic integration to induce loss of p53(via sh P53), activation of Notch [via intracellular domain of Notch1(NICD)] and/or overexpression of IDH1R132 C mutant together with the sleeping beauty transposase into the mouse liver. Specifically, we co-expressed sh P53 and NICD(sh P53/NICD, n = 4), sh P53 and IDH1R132C(sh P53/IDH1R132 C, n = 3), NICD and IDH1R132C(NICD/IDH1R132 C, n = 4), as well as NICD, sh P53 and IDH1R132C(NICD/sh P53/IDH1R132 C, n = 9) in mice. Mice were monitored for liver tumor development and euthanized at various time points. Liver histology was analyzed by hematoxylin and eosin staining. Molecular features of NICD/sh P53/IDH1R132 C ICC tumor cells were characterized by Myc tag, Flag tag, Ki-67, p-Erk and p-AKT immunohistochemical staining. Desmoplastic reaction in tumor tissues was studied by Picro-Sirius red staining.RESULTS: We found that co-expression of sh P53/NICD, sh P53/IDH1R132 C or NICD/IDH1R132 C did not lead to liver tumor formation. In striking contrast, coexpression of NICD/sh P53/IDH1R132 C resulted in ICC development in mice(P < 0.01). The tumors could be identified as early as 12 wk post hydrodynamic injection. Tumors rapidly progressed, and by 18 wk post hydrodynamic injection, multiple cystic lesions could be identified on the liver surface. NICD/sh P53/IDH1R132 C liver tumors shared multiple histological features of human ICCs, including hyperplasia of irregular glands. Importantly, all tumor cells were positive for the biliary epithelial cell marker cytokeratin 19. Extensive collagen fibers could be visualized in tumor tissues using Sirus red staining, duplicating the desmoplastic reaction observed in human ICC. Tumors were highly proliferative and expressed ectopically injected genes. Together these studies supported that NICD/sh P53/IDH1R132 C liver tumors were indeed ICCs. Finally, no p-AKT or p-ERK positive staining was observed, suggesting that NICD/sh P53/IDH1R132 C driven ICC development was independent of AKT/m TOR and Ras/MAPK signaling cascades. CONCLUSION: We have generated a simple, nongermline murine ICC model with activated Notch, loss of p53 and IDH1R132 C mutant. The study supported the oncogenic potential of IDH1R132 C. AIM: To investigate whether IDH1R132 C mutant in combination with loss of p53 and activated Notch signaling promotes intrahepatic cholangiocarcinoma(ICC) development.METHODS: We applied hydrodynamic injection and sleeping beauty mediated somatic integration to induce loss of p53(via sh P53), activation of Notch [via intracellular domain of Notch1(NICD)] and/or overexpression of IDH1R132 C mutant together with the sleeping beauty transposase into the mouse liver. Specifically, we co-expressed sh P53 and NICD(sh P53/NICD, n = 4), sh P53 and IDH1R132C(sh P53/IDH1R132 C, n = 3), NICD and IDH1R132C(NICD/IDH1R132 C, n = 4), as well as NICD, sh P53 and IDH1R132C(NICD/sh P53/IDH1R132 C, n = 9) in mice. Mice were monitored for liver tumor development and euthanized at various time points. Liver histology was analyzed by hematoxylin and eosin staining. Molecular features of NICD/sh P53/IDH1R132 C ICC tumor cells were characterized by Myc tag, Flag tag, Ki-67, p-Erk and p-AKT immunohistochemical staining. Desmoplastic reaction in tumor tissues was studied by Picro-Sirius red staining.RESULTS: We found that co-expression of sh P53/NICD, sh P53/IDH1R132 C or NICD/IDH1R132 C did not lead to liver tumor formation. In striking contrast, coexpression of NICD/sh P53/IDH1R132 C resulted in ICC development in mice(P < 0.01). The tumors could be identified as early as 12 wk post hydrodynamic injection. Tumors rapidly progressed, and by 18 wk post hydrodynamic injection, multiple cystic lesions could be identified on the liver surface. NICD/sh P53/IDH1R132 C liver tumors shared multiple histological features of human ICCs, including hyperplasia of irregular glands. Importantly, all tumor cells were positive for the biliary epithelial cell marker cytokeratin 19. Extensive collagen fibers could be visualized in tumor tissues using Sirus red staining, duplicating the desmoplastic reaction observed in human ICC. Tumors were highly proliferative and expressed ectopically injected genes. Together these studies supported that NICD/sh P53/IDH1R132 C liver tumors were indeed ICCs. Finally, no p-AKT or p-ERK positive staining was observed, suggesting that NICD/sh P53/IDH1R132 C driven ICC development was independent of AKT/m TOR and Ras/MAPK signaling cascades. CONCLUSION: We have generated a simple, nongermline murine ICC model with activated Notch, loss of p53 and IDH1R132 C mutant. The study supported the oncogenic potential of IDH1R132 C.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第6期2071-2080,共10页 世界胃肠病学杂志(英文版)
基金 Supported by Grants from National Institutes of Health No.R01CA136606(in part to Chen X) UCSF Liver Center No.P30DK026743 China Scholarship Council contract No.201206010086(to Ding N)and No.201306590021(to Li XL)
关键词 IDH1 MUTANT NOTCH PATHWAY Intrahepaticcholangiocarcinoma MOUSE LIVER cancer p53 IDH1 mutant Notch pathway Intrahepatic cholangiocarcinoma Mouse liver cancer p53
  • 相关文献

参考文献47

  • 1Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Geneticheterogeneity in cholangiocarcinoma: a major challenge for targetedtherapies. Oncotarget 2015; 6: 14744-14753 [PMID: 26142706].
  • 2Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet2014; 383: 2168-2179 [PMID: 24581682 DOI: 10.1016/S0140-6736(13)61903-0].
  • 3Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M,Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement.HPB (Oxford) 2015; 17: 691-699 [PMID: 26172136 DOI: 10.1111/hpb.12450].
  • 4Woo SM, Lee WJ, Kim JH, Kim DH, Han SS, Park SJ, Kim TH,Lee JH, Koh YH, Hong EK. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advancedbiliary tract cancer: a retrospective cohort study. Chemotherapy2013; 59: 232-238 [PMID: 24356333 DOI: 10.1159/000354539].
  • 5Valle JW. BINGO: targeted therapy for advanced biliary-tractcancer. Lancet Oncol 2014; 15: 778-780 [PMID: 24852117 DOI:10.1016/S1470-2045(14)70238-4].
  • 6Kongpetch S, Jusakul A, Ong CK, Lim WK, Rozen SG, Tan P,Teh BT. Pathogenesis of cholangiocarcinoma: From genetics tosignalling pathways. Best Pract Res Clin Gastroenterol 2015; 29:233-244 [PMID: 25966424 DOI: 10.1016/j.bpg.2015.02.002].
  • 7Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma:molecular pathways and therapeutic opportunities. SeminLiver Dis 2014; 34: 456-464 [PMID: 25369307 DOI: 10.1055/s-0034-1394144].
  • 8Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM,Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX,Hezel AF. Mutational profiling reveals PIK3CA mutations ingallbladder carcinoma. BMC Cancer 2011; 11: 60 [PMID: 21303542DOI: 10.1186/1471-2407-11-60].
  • 9Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D,Witzigmann H, Hauss J, Wittekind C. Mutations of the BRAF genein cholangiocarcinoma but not in hepatocellular carcinoma. Gut2003; 52: 706-712 [PMID: 12692057].
  • 10Tannapfel A, Weinans L, Geissler F, Schütz A, Katalinic A,K-ckerling F, Hauss J, Wittekind C. Mutations of p53 tumorsuppressor gene, apoptosis, and proliferation in intrahepaticcholangiocellular carcinoma of the liver. Dig Dis Sci 2000; 45:317-324 [PMID: 10711445].

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部